MedTrace Logo

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

NCT03135548 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-10-16

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Conditions

Interventions

DRUG

Spesolimab (low dose)

12 weeks treatment

DRUG

Placebo

12 weeks treatment

DRUG

Spesolimab (high dose)

12 weeks treatment

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-30
Primary Completion
2018-07-12
Completion
2018-11-14

Countries

  • Canada
  • Denmark
  • Germany
  • Italy
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03135548 on ClinicalTrials.gov